Citação de: Special_one em 2012-12-17 21:27:42Citação de: Special_one em 2012-12-11 18:20:03DNDN parece que esta a iniciar um novo arranque o fecho de hoje poderá ser uma excelente entrada, Stop a 4.25 Esta prepara-se para ir fechar os gap nos 6$ Stop passa para 4.85 Mais um belo fecho a caminho do fecho do gap
Citação de: Special_one em 2012-12-11 18:20:03DNDN parece que esta a iniciar um novo arranque o fecho de hoje poderá ser uma excelente entrada, Stop a 4.25 Esta prepara-se para ir fechar os gap nos 6$ Stop passa para 4.85
DNDN parece que esta a iniciar um novo arranque o fecho de hoje poderá ser uma excelente entrada, Stop a 4.25
Qual a tua opinião sobre a SNTI?
On that issue we provide a preliminary report on Senesco Technologies (SNTI) this AM Much has happened in the Senesco world in 2013. The company completed its cohort 3 testing (a 1B/2A trial) on SNST-01 successfully. Perhaps most important, the results of cohort 3 indicate that the company’s Factor 5A therapy leaves healthy cells untouched and appears to positively treat cells marked for apoptosis (cancer cells) in humans. The increased dosage of SNS01-T in he current cohort 4 test will tell us much more about the effectiveness of the therapy. On the whole, however, there is significant optimism about the impact of the Factor 5A therapy on cancer cells, in this case multiple myeloma and two other blood cancers. In 2013 we saw a 100 to 1 reverse split that reduced outstanding shares from 500 million to ~ 5 million to recapitalize the company. In addition Dr Phil Frost (Chairman of Teva Pharmaceuticals) has participated in a significant fund raise for Senesco. Finally, yesterday the company announced a letter of intent for a merger with another company that will extend the research capability and ultimately the range of products significantly if the merger goes to fruition likely in February. We think the company has market momentum now. Cancer therapies are behavioral in nature. By that I mean that value creation is in the mind of the investor. The word “cancer” carries with it a dread that any potentially effective cancer therapy benefits from in its markets. That is where Senesco is positioned today even though pre clinical research at the University of Virginia in the past has shown many more potential applications including a suppression of the immune systems cytokine flood and potential for treatment of diabetes. These vast differences in apparent application make the Senesco Factor 5A technology a multi –billion dollar market cap potential. For now we await the results of Cohort 4 tests on blood cancers which we expect to see by midyear or earlier. We are buyers of Senesco Technologies within the next 24 hours. The stock is clearly a buy at these levels with a market cap of $30 million. On January 20th in Vancouver I will present a paper on the development of wealth through Senesco Technologies. I own shares in Senesco Technologies.
Pfizer's (PFE +1.4%) Palbociclib drug for treating breast cancer demonstrated statistically significant improvement in patients' progression-free survival rates in a Phase II trial.Palbociclib was tested in post-menopausal women in combination with the hormonal therapy Letrozole; the control group received just the latter drug.Analysts reckon that Pfizer might now seek accelerated approval for Palbociclib, whose importance has increased following the recent failure of Dacomitinib in two late-stage lung-cancer trials.Adam Feuerstein notes that Amgen (AMGN) owns a piece of Palbociclib via the acquisition of Onyx. (PR)
U.S. asks jurors to convict SAC's Martoma By Nate Raymond NEW YORK, Feb 3 (Reuters) - Mathew Martoma sought out a "canary in the coal mine" to give him inside information on drug companies, a federal prosecutor said on Monday, urging jurors to convict the former SAC Capital Advisors portfolio manager of insider trading. Martoma, 39, built up contacts with doctors involved in a clinical trial of an Alzheimer's drug, which paid off in a "dramatic way" when one of them told him the final results, Assistant U.S. Attorney Eugene Ingoglia said. "Martoma then used this information for his financial benefit," Ingoglia said. Ingoglia was summarizing the government's case after four weeks of trial over what prosecutors call the most lucrative insider trading episode in U.S. history. Martoma is accused of using confidential information to trade the stocks of the drug's developers, Elan Corp Plc <ELNCF.PK> and Wyeth, which is now owned by Pfizer Inc <PFE.N>. Based on that information, SAC Capital made profits and avoided losses of about $275 million. Martoma has denied wrongdoing. His lawyer, Richard Strassberg, told jurors the entire case came down to the testimony of a single doctor who cooperated with the government and whose "testimony cannot be believed." "If beyond a reasonable doubt means anything, then it's that the prosecution has failed to prove its case against Mathew Martoma," Strassberg said. With Martoma's wife, Rosemary, looking on, Ingoglia told a packed courtroom that Martoma had "corrupted" two doctors involved in the trial beginning in 2006. After an earlier trial for an Alzheimer's drug developed by Elan had been halted due to safety issues, "Martoma needed the equivalent of a canary in the coal mine," Ingoglia said. Martoma began speaking with Joel Ross, a clinical investigator on the trial who oversaw patients at his clinic in Eatontown, New Jersey. Ross, 58, earned $1,500 an hour to speak with Martoma, Ingoglia said. Ross also "very badly" wanted Martoma to help use his contacts to bring business to his newest clinic, he said. "He was going to return the favor or return the courtesy by giving insider information to Mr. Martoma," Ingoglia said. Ingoglia said Martoma received "an illegal sneak preview" in July 2008 of negative results of the drug trial from Sidney Gilman, then a professor at University of Michigan who chaired the drug trial's safety monitoring committee. SAC Capital then began selling off its $700 million position in Elan and Wyeth before the data was made public later that month, Ingoglia said. Most of the trading took place in accounts controlled by Steven A. Cohen, the founder of SAC Capital Advisors, who was informed about the negative results by Martoma during a 20-minute telephone call, Ingoglia said. Gilman, 81, testified under a non-prosecution agreement, as did Ross. But Strassberg said "there are so many inconsistencies and so many changes" in the testimony by Gilman, whose memory became an issue at trial. "It is just Dr. Gilman's testimony, and that testimony cannot be believed," Strassberg said. Cohen, 57, has not been criminally charged. The U.S. Securities and Exchange Commission is seeking to bar him from the financial services industry for failing to supervise Martoma and Steinberg. Cohen has denied wrongdoing. SAC Capital agreed last year to pay $1.8 billion in criminal and civil settlements and plead guilty to fraud charges stemming from insider trading by its employees. The case is U.S. v. Martoma, U.S. District Court, Southern District of New York, 12-cr-00973.
EXEL voltou a mexer hoje ...pode ter uma bela subida .THLD, IMUC, TXMD,SNSS, HEB e PTIE são outras que podem disparar a qualquer momento
Citação de: Happy_one em 2015-01-28 23:09:55EXEL voltou a mexer hoje ...pode ter uma bela subida .THLD, IMUC, TXMD,SNSS, HEB e PTIE são outras que podem disparar a qualquer momentoExel a mexer de novo ....as anteriores acrescento a AMRN
